Featured Research

from universities, journals, and other organizations

Early antiretroviral therapy for HIV shown cost-effective, Haiti study finds

Date:
September 22, 2011
Source:
Weill Cornell Medical College
Summary:
Researchers in the U.S. and Haiti have shown that early treatment of HIV not only saves lives but is also cost-effective.

Researchers at Weill Cornell Medical College and GHESKIO (Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes) have shown that early treatment of HIV not only saves lives but is also cost-effective.

Related Articles


Results are published in the online journal PLoS Medicine.

Before 2009, the World Health Organization (WHO) recommended waiting to initiate antiretroviral therapy (ART) for HIV until a patient's CD4+ T cells fall below 200 cells per cubic millimeter. But in that year, a randomized clinical trial completed by Weill Cornell researchers at the GHESKIO clinic in Port-au-Prince, Haiti, demonstrated that early ART decreased mortality by 75 percent in HIV-infected adults with a CD4 cell count between 200 and 350 cells/mm3. As a result, the WHO now recommends that ART is started in HIV-infected people when their CD4 cell count falls below 350 cells/mm3.

The new study, conducted by researchers at Weill Cornell Medical College, GHESKIO, and Brigham and Women's Hospital in Boston sought to evaluate if the revised WHO recommendation is cost-effective and if its benefits outweigh its costs. A medical intervention is generally considered cost-effective if it costs less than three times a country's per capita gross domestic product (GDP) per year of life saved (YLS).

The researchers used data from the previous randomized trial to compare the cost-effectiveness of early versus standard ART. They included in their analysis the use and costs of ART, other medications, laboratory tests, outpatient visits, radiography, procedures and hospital services. Patients who received early ART had higher average costs for ART but lower costs for other aspects of their treatment than patients who received standard ART. When the costs of research-related tests were excluded, the incremental cost-effectiveness ratio after three years for early ART compared with standard ART was US $2,050/YLS.

"Because the Haitian GDP per capita is US $785, these findings suggest that, in Haiti, early ART is a cost-effective intervention over the observation period of the trial," says lead author Dr. Serena P. Koenig, assistant professor at Brigham and Women's Hospital.

"The incremental cost-effectiveness ratios calculated in our study are probably conservative because they did not consider the clinical benefits of early ART that continue beyond three years -- early ART is associated with lower longer-term mortality than standard ART -- or the benefit of early ART on disability and quality of life," says senior author Dr. Bruce R. Schackman, associate professor of public health and chief of the Division of Health Policy at Weill Cornell Medical College.

"This study suggests that the new WHO guidelines for ART initiation can be cost-effective in resource-poor settings," says Dr. Jean W. Pape, founder and director of GHESKIO and professor of medicine at Weill Cornell Medical College. "Despite substantial budget and logistical constraints to implementing earlier treatment," he continues, "policymakers should allocate resources to maximize their ability to implement the new guidelines."

The paper's other authors are, from Weill Cornell Medical College, Dr. Daniel W. Fitzgerald, Dr. Warren D. Johnson, Dr. Jean W. Pape, Dr. Heejung Bang and Ms. Alison Edwards; and from GHESKIO, Dr. Patrice Severe, Dr. Marc Antoine Jean Juste, Dr. Alex Ambroise, Dr. Cynthia Riviere, Ms. Jessica Hippolyte, Mr. Jolion McGreevy, Mr. Serge Marcelin and Dr. Rode Secours.

Funding for the study was provided by the U.S. National Institutes of Allergy and Infectious Diseases, the Fogarty International Center, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Fondation Mιrieux, among others.

Founded in 1982, GHESKIO (Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, or the Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections) is a nongovernmental research and training center internationally recognized for its pioneering work in the treatment of HIV and AIDS-related illnesses. GHESKIO maintains a close relationship with Weill Cornell Medical College. Its founding director, Dr. Jean Pape, is a professor of medicine at Weill Cornell Medical College. Since its inception, GHESKIO has never closed its doors to patients, not even during the 7.0 magnitude earthquake that struck Haiti in 2010.


Story Source:

The above story is based on materials provided by Weill Cornell Medical College. Note: Materials may be edited for content and length.


Journal Reference:

  1. Serena P. Koenig, Heejung Bang, Patrice Severe, Marc Antoine Jean Juste, Alex Ambroise, Alison Edwards, Jessica Hippolyte, Daniel W. Fitzgerald, Jolion McGreevy, Cynthia Riviere, Serge Marcelin, Rode Secours, Warren D. Johnson, Jean W. Pape, Bruce R. Schackman. Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. PLoS Medicine, 2011; 8 (9): e1001095 DOI: 10.1371/journal.pmed.1001095

Cite This Page:

Weill Cornell Medical College. "Early antiretroviral therapy for HIV shown cost-effective, Haiti study finds." ScienceDaily. ScienceDaily, 22 September 2011. <www.sciencedaily.com/releases/2011/09/110921093554.htm>.
Weill Cornell Medical College. (2011, September 22). Early antiretroviral therapy for HIV shown cost-effective, Haiti study finds. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2011/09/110921093554.htm
Weill Cornell Medical College. "Early antiretroviral therapy for HIV shown cost-effective, Haiti study finds." ScienceDaily. www.sciencedaily.com/releases/2011/09/110921093554.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins